This paper describes the isolation and purification, and the physicochemical and biological nronerties of these four new anthracvclines. Isolation and Purification
The fer-nentation broth of Micromonospora3), was filtered with filter aid at pH 4 and the yellow pigments were extracted from the mycelium with an acetone -0.1 y hydrochloric acid mixture (4: 1, v/v).
The extract, adjusted to pH 4.5, was concentrated under reduced pressure and the aqueous concentrate Table 2 .
Aqueous acid hydrolysis (0.2 N HCl, 1 hour, 90°C) of the four glycosides gave different water insoluble aglycones, whose chemical and physical properties are summarized in Table 3 , and the same reducing arninosugar which was identified as daunosamine5°, previously found in daunorubicin and doxorubicin. Further structural studies4) assigned to the aglycones of glycosides A, B, C and D the VOL. XXXIII NO. 12 THE JOURNAL OF ANTIBIOTICS structures of 11-deoxyadriamycinone, 11-deoxy-13-dihydrodaunomycinone, 11-deoxydaunomycinone, and I1-deoxy-13-deoxodaunomycinone, respectively.
Biological Activity Data
Antibacterial Activity
The new anthracyclines displayed a low antibacterial activity. Their in vitro minimal inhibitory concentration (MIC) values on some microorganisms, using the standard tube dilution procedure, are reported in Table 4 . In brackets, range of individual experiments.
Antitumor Activity
The cytotoxic activity of I1-deoxydoxorubicin (I), 11-deoxydaunorubicin (III) and its analogues substituted in position 13 was compared with that of doxorubicin and daunorubicin on HeLa cells in vitro and the results are reported in Table 5 . All the 11-deoxy derivatives tested were markedly less effective than the parent antibiotics on HeLa cells cloning efficiency.
11-Deoxydaunorubicin and l1-deoxydoxorubicin were also tested against P388 ascitic leukemia in mice. The results, reported in Table 6 , show that the new anthracyclines were markedly less potent than the parent compounds: 11-deoxydaunorubicin was 15-times less potent than daunorubicin and 11-deoxydoxorubicin 60-times less potent than doxorubicin (ratio between optimal non toxic doses).
At the optimal doses, however, the I 1-deoxy derivatives maintained an antitumor activity of the same order of magnitude as that of the parent compounds.
In conclusion, the absence of the hydroxy group in position 11 of daunorubicin and doxorubicin caused a remarkable reduction of the potency in vitro and in vivo, but did not hamper the antitumor activity.
Whether the reduced potency is due to decreased cell uptake or to reduced ability of binding to DNA remains to be determined.
